Drug Trial Radar · NCT07943598
A Global Phase 2 Extension Study of Brogidirsen in Boys With Duchenne Muscular Dystrophy
Last checked: Nov 19, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Enrolling by invitation
Enrollment
20
Planned (sponsor's estimate)
Start
Dec 16, 2026
Primary completion
Sep 3, 2029
Study completion Sep 3, 2029
Sponsor
- Lead sponsor
- NS Pharma, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Nippon Shinyaku Co., Ltd.
- First posted
- Nov 17, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This Phase 2, open-label, multi-center extension study will be conducted in boys with DMD who completed the 24-week Treatment Period of Study NS-089/NCNP-02-201. Brogidirsen will be administered by IV infusion once weekly for up to 120 weeks (up to a total of 144 weeks of treatment, including weekly dosing from Part 2 of Study NS-089/NCNP-02-201) or until brogidirsen is commercially available, whichever is earlier.
Conditions
- Duchenne Muscular Dystrophy
- Exon 44
- DMD
Interventions
BrogidirsenDrug
Brogidirsen will be administered for up to 120 weeks (up to a total of 144 weeks of treatment, including weekly dosing from Part 2 of Study NS-089/NCNP-02-201) or until Brogidirsen is commercially available, whichever is earlier.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs)Time frame: Through study completion, an average of 124 weeks
- Change in baseline in the following assessments: 12-lead electrocardiograms (ECGs), Vital signs, Physical and neurological examinations, Clinical laboratory testsTime frame: Through study completion, an average of 120 weeks
Locations
17 sites in 7 countries. Site status is shown where the registry gives one.
Children's Hospital Colorado
Aurora, Colorado
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio
Virginia Commonwealth University Health System
Richmond, Virginia
Queensland Children's Hospital
South Brisbane, Queensland, Australia
British Columbia Children's Hospital
Vancouver, British Columbia, Canada
London Health Sciences Centre
London, Ontario, Canada
Fukui Prefectural Hospital
Fukui-shi, Fukui, Japan
NHO Nagara Medical Center
Nagara, Gifu-shi, Gifu, Japan
NHO Osaka Toneyama Medical Center
Toyonaka, Osaka, Japan
Shiga General Hospital
Moriyama-shi, Shiga, Japan
National Center of Neurology and Psychiatry
Kodaira, Tokyo, Japan
Starship Children's Hospital
Auckland, New Zealand
Seoul National University Hospital
Seoul, South Korea
Pusan National University Yangsan Hospital
Yangsan, Gyeongsangnam, South Korea
Ankara Bilkent City Hospital
Ankara, Turkey, Turkey (Türkiye)
Yeditepe University Kosuyolu Hospital
Istanbul, Turkey, Turkey (Türkiye)
S.B.U. Dr. Behcet uz Pediatric Diseases and Surgery Training and Research Hospital
Izmir, Turkey, Turkey (Türkiye)
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.